NewEdge Advisors LLC Has $13.71 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• NewEdge Advisors increased its Bristol Myers Squibb stake by 12.9% in the first quarter, bringing its holdings to 226,056 shares valued at approximately $13.71 million. Institutional investors and hedge funds collectively own 76.41% of BMY.
• Analyst sentiment is broadly positive: BMY has a “Moderate Buy” consensus rating and an average price target of $66.06, with Argus upgrading the stock to Buy and several firms raising their targets.
• Recent financial results exceeded expectations. Bristol Myers Squibb reported quarterly EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion, up 5.7% year over year; it also maintains a $2.52 annual dividend, yielding about 3.9%.

NewEdge Advisors LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 12.9% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 226,056 shares of the biopharmaceutical company's stock after buying an additional 25,771 shares during the quarter. NewEdge Advisors LLC's holdings in Bristol Myers Squibb were worth $13,710,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Brighton Jones LLC increased its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock valued at $346,000 after buying an additional 2,786 shares during the period. United Bank grew its position in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock worth $1,164,000 after buying an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new position in Bristol Myers Squibb during the 2nd quarter worth $221,000. Finally, Nebula Research & Development LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on BMY shares. TD Cowen began coverage on Bristol Myers Squibb in a research report on Wednesday. They set a "buy" rating for the company. Argus raised Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target for the company in a research note on Wednesday. Cantor Fitzgerald reiterated a "neutral" rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Truist Financial reissued a "buy" rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Royal Bank Of Canada boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $66.06.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Bristol Myers Squibb Trading Up 0.7%

BMY opened at $64.63 on Friday. The company's 50 day moving average is $58.71 and its 200-day moving average is $58.64. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.10. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company has a market cap of $132.02 billion, a P/E ratio of 14.24, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.96 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source